Government to Establish Two Pharmaceutical Hubs Under US$1bn Compact to Slash GH¢5bn Import Bill

Ghana will establish two pharmaceutical and biomanufacturing hubs in the Eastern and Central Regions as part of a US$1 billion compact aimed at cutting the country’s GH¢5 billion annual medicine…

Published 4 min read

Government to Establish Two Pharmaceutical Hubs Under US$1bn Compact to Slash GH¢5bn Import Bill

Ghana will establish two pharmaceutical and biomanufacturing hubs in the Eastern and Central Regions as part of a US$1 billion compact aimed at cutting the country’s GH¢5 billion annual medicine import bill and positioning it as a manufacturing base for West Africa.

The hubs, designated special economic zones, will provide industrial infrastructure for local and international drug makers, with opportunities in contract manufacturing, research and development, and the production of medicines and vaccines. A state-owned special purpose vehicle is expected to begin construction in 2027, according to the 2027 Budget Statement, which names the two regions as locations. Qualified Ghanaian and international manufacturers will participate through transparent lease and operating agreements.

“Golden Era” for the Industry

Addressing the 2026 National Pharmacy Heads’ Retreat in Accra as special guest of honour, the Presidential Coordinator of the Ghana Pharmaceutical Hub, Dr Bernice Makafui Brempong, said the zones would anchor a transformation of the sector. “We are in the golden era of the pharmaceutical industry,” she said, adding that President John Dramani Mahama is committed to the agenda.

Dr Brempong estimated that Ghana spends about GH¢5 billion a year on pharmaceutical products from India and China, and argued that expanding domestic manufacturing would keep a significant share of that spending at home. “This will create jobs for our people and foreign exchange for the country,” she said.

A Market Dominated by Imports

The initiative responds to a stark reality: Ghana currently imports between 70 and 75 per cent of its medicine requirements, costing the country approximately US$500 million annually. The Ghanaian pharmaceutical market is made up of roughly 30 per cent locally produced and 70 per cent imported products, with the bulk of imports—predominantly low-value generic drugs—originating from India, China and the European Union.

Local manufacturers have long been constrained by four major challenges: the high cost of imported raw materials, expensive financing, limited product diversification, and gaps in technology and specialised skills. The sector, which is the second-largest in West Africa after Nigeria, had 40 registered manufacturing companies as of 2020, directly employing more than 10,000 people and indirectly supporting approximately 100,000 livelihoods.

From 30% to 60–80% Local Production

The broader ambition of the compact is to raise the share of Ghana’s essential medicine needs produced locally to between 60 and 80 per cent by 2030, while building the capacity to supply pharmaceutical products to other African markets. The initiative is also expected to generate about 20,000 direct and indirect jobs.

The government plans to amend public procurement laws to make locally manufactured medicines the preferred option for state-funded purchases, provided they are available in sufficient quantities and meet approved quality standards. All suppliers will be required to obtain Food and Drugs Authority registration and comply with Good Manufacturing Practice standards, and local manufacturers will be supported to attain World Health Organisation prequalification to compete in regional and international markets.

Finance Minister Dr Cassiel Ato Forson, who announced the compact during the 2027 Budget presentation on November 12, cited India, Ethiopia, Nigeria and Tanzania as countries that have successfully used procurement preferences to support local pharmaceutical production.

Healthcare Reforms Depend on Medicine Supply

Dr Brempong linked the push to new demand generated by the government’s healthcare initiatives—Free Primary Healthcare, the Ghana Medical Trust Fund, Mahama Cares, a strengthened National Health Insurance Scheme, and 24-Hour Health Services—saying the systems and workforce behind them must be reinforced. The Hub, approved as a Presidential National Legacy Flagship Initiative, is designed to organise the market, secure demand, finance capacity, manufacture medicines, and supply Ghana, West Africa and the wider continent, while protecting the jobs and livelihoods of medicine importers, distributors and their employees.

Dr Martha Gyansa-Lutterodt, Chairperson for the occasion, stressed that a reliable pharmaceutical supply system is essential to the success of the reforms. Free primary healthcare, she argued, can only deliver on its promise if patients consistently get the medicines they need, use them safely and complete treatment without interruption. Free care, she said, should not mean “out of stock,” and achieving that requires a competent pharmaceutical workforce and systems built around reliable, safe and patient-centred care.

The compact builds on a Pharmaceutical Manufacturing Policy launched in October 2026, which seeks to increase the local market share of Ghanaian-made medicines from about 30 per cent to 60 per cent and double pharmaceutical exports to ECOWAS markets. With construction set to begin next year, the government’s challenge will be to translate the ambition into factories, jobs and reliable medicine shelves—and to ensure that the “golden era” reaches the patients who need it most.

Share this story

Get the AfroAsia Media newsletter

The day's top stories from Africa and Asia, straight to your inbox.

Comments

0 comments

Loading…